DAXOR CORP 10-Q Summary: Quarter Ended September 30, 2003
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2003, for DAXOR Corporation, a New York-based company. The firm operates in two primary segments: the development and marketing of the BVA-100 Blood Volume Analyzer and related kits, and the provision of localized semen and blood banking services. The company is actively expanding its sales force to promote the BVA-100 as a standard of care in medicine and surgery.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2003 | Nine Months Ended Sep 30, 2003 |
|---|---|---|
| Total Revenues | $904,183 | $2,413,467 |
| Operating Revenues | $301,816 | $810,910 |
| Dividend Income | $527,591 | $1,438,232 |
| Net Income (Loss) | $(180,041) | $(702,280) |
| Net Income (Loss) Per Share | $(0.04) | $(0.15) |
| Total Assets | $45,370,353 (as of Sep 30, 2003) | |
| Shareholders' Equity | $34,734,103 (as of Sep 30, 2003) | |
| Cash and Cash Equivalents | $52,692 (as of Sep 30, 2003) | |
| Marketable Securities (Fair Value) | $44,293,770 (as of Sep 30, 2003) | |
| Total Liabilities | $10,636,250 (as of Sep 30, 2003) | |
| Loans Payable | $2,708,910 (as of Sep 30, 2003) |
Material Changes vs. Prior Period
- Revenue Growth: Operating revenues increased 51% in the three-month period ($301,816 vs. $200,100) and 37% in the nine-month period ($810,910 vs. $589,604) compared to the prior year, attributed to a new sales team and marketing efforts.
- Profitability Decline: Despite revenue growth, the company reported a net loss of $180,041 for the quarter and $702,280 for the nine months, contrasting with net income of $105,009 and $215,674, respectively, in the prior year periods.
- Expense Increases: Total costs and expenses rose significantly to $1,085,082 (quarter) and $3,094,960 (nine months) due to increased marketing, research and development (R&D) for the BVA-100, and the hiring of additional personnel.
- Investment Portfolio: The company holds a significant portfolio of marketable securities valued at $44.3 million, representing a net unrealized gain of $21.9 million (97.48% over cost). This portfolio is a major component of the company's equity.
- Liquidity: Cash on hand is low at $52,692, but the company maintains substantial liquid assets in marketable securities. Loans payable increased to $2.7 million, primarily margin debt secured by the securities portfolio.
Outlook, Risks, and Management Commentary
- Strategic Focus: Management anticipates that sales of the BVA-100 and kits will become the major income source. The company is expanding its sales force and support services.
- Revenue Recognition: The company utilizes a leasing and "loaner reagent" plan to lower barriers for hospital adoption. While this aids sales, it results in slower recognition of operating income and a slower return on capital expenditure.
- Capital Resources: The company states it has adequate resources to sustain current marketing levels and operations. Future capital will be used primarily for developing and marketing the Blood Volume Analyzer.
- Risks: The company relies heavily on its investment portfolio for liquidity and equity value. A significant portion of liabilities ($7.4 million) consists of deferred taxes that would be triggered if the entire securities portfolio were sold. Sales cycles for the BVA-100 are long (6 to 12 months).
- Legal Proceedings: The filing reports no pending legal proceedings.
Investor Verification Checklist
- Investment Portfolio Valuation: Verify the fair value and unrealized gains of the $44.3 million securities portfolio, as this drives the majority of the company's equity and liquidity.
- Debt Covenants: Review the terms of the $2.7 million in loans payable, which are secured by the marketable securities, to understand margin call risks.
- Operating Cash Flow: Note that operating cash flow was negative ($763,842 used) for the nine months; verify the sustainability of operations without selling securities.
- Deferred Tax Liability: Assess the impact of the $7.4 million deferred tax liability on net equity if the company decides to liquidate its investment portfolio.
- Sales Pipeline: Monitor the conversion rate of the expanded sales team and the timeline for BVA-100 revenue recognition given the 6-12 month sales cycle.